HER2 assessment to define outcomes for breast cancer patients treated with neoadjuvant therapy

被引：0
|
作者：
Cheng, Huan [1 ]
Bai, Yalai [1 ]
Sikov, Willliam [2 ]
Sinclair, Natalie [2 ]
Abu-Khalaf, Maysa [1 ]
Harris, Lyndsay N. [1 ]
Rimm, David L. [1 ]
机构：
[1] Yale Univ, New Haven, CT USA
[2] Brown Univ, Providence, RI 02912 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-705
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
705
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The influence of hormone receptor status and HER1 and HER2 expression on the response to neoadjuvant therapy in breast cancer patients
    Bouiglieri, L.
    Torrisi, R.
    Pruneri, G.
    Colleoni, M.
    Viale, G.
    MODERN PATHOLOGY, 2008, 21 : 24A - 24A
  • [42] Assessment of HER2 status in breast cancer
    Penault-Llorca, F
    Cayre, A
    BULLETIN DU CANCER, 2004, 91 : S211 - S215
  • [43] Molecular Assessment of HER2 in Breast Cancer
    Maddox, Adam L.
    Brehove, Matthew S.
    Tobin, Steven J.
    Wakefield, Devin L.
    Eliato, Kiarash R.
    Alva-Ornelas, Jackelyn
    Jones, Veronica
    Schmolze, Daniel
    Mortimer, Joanne
    Seewaldt, Victoria L.
    Jovanovic-Talisman, Tijana
    BIOPHYSICAL JOURNAL, 2021, 120 (03) : 359A - 359A
  • [44] HER2 as a target for breast cancer therapy
    Tagliabue, Elda
    Balsari, Andrea
    Campiglio, Manuela
    Pupa, Serenella M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (05) : 711 - 724
  • [45] Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer reply
    Baselga, Jose
    de Azambuja, Evandro
    Bradbury, Ian
    Gelber, Richard
    LANCET, 2012, 379 (9833): : 2238 - 2238
  • [46] Gain of HER2 Amplification in Patients with HR+/HER2-and Triple Negative Early Breast Cancer Treated with Neoadjuvant Chemotherapy
    Ferraro, Emanuela
    Minmin, Sonya Chew
    Safonov, Anton
    Barrio, Andrea V.
    Modi, Shanu
    Seidman, Andrew D.
    Wen, Hanna Y.
    Brogi, Edi
    Robson, Mark E.
    Dang, Chau T.
    CANCER RESEARCH, 2023, 83 (05)
  • [47] Outcomes of patients with HER2 positive metastatic breast cancer treated with low dose or metronomic lapatinib
    Mathew, S. P.
    Avaronnan, M.
    Shenoy, P. K.
    Devi R, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S1439 - S1439
  • [48] Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Melissa Krystel-Whittemore
    Jin Xu
    Edi Brogi
    Katia Ventura
    Sujata Patil
    Dara S. Ross
    Chau Dang
    Mark Robson
    Larry Norton
    Monica Morrow
    Hannah Y. Wen
    Breast Cancer Research and Treatment, 2019, 177 : 61 - 66
  • [49] Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Krystel-Whittemore, Melissa
    Xu, Jin
    Brogi, Edi
    Ventura, Katia
    Patil, Sujata
    Ross, Dara S.
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Wen, Hannah Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (01) : 61 - 66
  • [50] Is HER2 loss after neoadjuvant chemotherapy determinant for the choice of adjuvant treatment in HER2 positive breast cancer patients?
    Altundag, Kadri
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (02) : 328 - 328
12345